Exploring potential therapeutics targeting corona virus Spike glyco proteins, and how they might be utilized for treatment of SARS-CoV-2
Abstract
The recent outbreak of the novel SARS-CoV-2 has resulted in a worldwide pandemic and left healthcare systems scrambling to cope with the sheer magnitude of the disease outbreak. Taxonomic analysis of SARS-CoV-2 showed it to be a successor of SARS-CoV which caused the 2003 SARS pandemic. SARS-CoV-2 viral entry into host cells is similar to related coronaviruses SARS-CoV and HCoV-NL63, with all three viruses utilizing Spike (S) glycoprotein to interact with ACE2 receptor. SARS-CoV-2 and SARS-CoV S glycoprotein also shares 77-80% primary amino acid sequence identity. Several therapeutics have been developed and shown to be effective against SARS-CoV and HCOV-NL63 viral entry. As such, we investigated the therapeutics targeting SARS-CoV and HCOV-NL63 coronavirus S glycoproteins for possible usage against SARS-CoV-2.
Keywords: corona virus
Biography:
Zhen Zong Lim is a 2nd year medical students from Imperial College London, UK with an interest in infectious disease, particularly in treatment and prevention.
11th International Conference on Emerging Infectious Diseases; Webinar- November 23-24, 2020.
Abstract Citation:
Zhen Zong Lim, Exploring potential therapeutics targeting coronavirus Spike glycoproteins, and how they might be utilized for treatment of SARS-CoV-2, Emerging Diseases 2020, 11th International Conference on Emerging Infectious Diseases; Webinar- November 23-24, 2020 (https://emerging-diseases.infectiousconferences.com/abstract/2020/exploring-potential-therapeutics-targeting-coronavirus-spike-glycoproteins-and-how-they-might-be-utilized-for-treatment-of-sars-cov-2)
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 1513
- [From(publication date): 0-2020 - Jul 17, 2024]
- Breakdown by view type
- HTML page views: 938
- PDF downloads: 575
